학술논문
Clinical and descriptive characteristics associated with high-grade meningioma in a large clinical series.
Document Type
Academic Journal
Author
Mokhtari S; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL, USA.; Peeri NC; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Beer-Furlan A; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL, USA.; Anderson MD; Department of Neuro-Oncology, University of Mississippi Medical Center, Jackson, MS, USA.; Chowdhary S; Neuro-Oncology Program, Lynn Cancer Institute, Boca Raton, FL, USA.; LaRocca RV; Norton Cancer Institute, Louisville, KY, USA.; Mammoser AG; Department of Neurosurgery, LSU Health Sciences Center, New Orleans, LA, USA.; Nabors LB; Neuro-Oncology Program, University of Alabama at Birmingham, Birmingham, AL, USA.; Olson JJ; Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.; Thompson RC; Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.; Thompson ZJ; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.; Martinez YC; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.; Egan KM; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Source
Publisher: Taylor & Francis Country of Publication: England NLM ID: 8800054 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1360-046X (Electronic) Linking ISSN: 02688697 NLM ISO Abbreviation: Br J Neurosurg Subsets: MEDLINE
Subject
Language
English
Abstract
Purpose: We studied 571 patients with intracranial meningioma for clinical characteristics and tumor location associated with high grade meningioma (WHO II/III).
Materials and Methods: Patients were participants in a multicentre epidemiologic study of risk factors for primary brain tumors including meningioma recruited from September 2005 to November 2019. We included patients 18 or older with a recent diagnosis of a primary intracranial meningioma of any subtype (ICD9/10: 9530-0, 9531-0, 9532-0, 9537-0, 9533-0, 9534-0, 9530-0, 9538-1, 9538-3) who were enrolled at neuro-oncology and neuro-surgery clinics in the southeastern U.S.
Results: The median patient age was 58 years (IQR: 48-68) and the majority of patients were female ( n = 415; 72.7%) and Caucasian ( n = 516; 90.4%). Most patients were symptomatic ( n = 460; 80.6%) and their tumours more commonly occurred in a non-skull base location ( n = 298; 52.2%). A total of 86 patients (15.0%) had a WHO grade II/III meningioma. Compared to patients with WHO grade I tumours, patients with WHO II/III meningiomas were over 3-times more likely to be male (odds ratio (OR): 3.25; 95% confidence interval (CI): 1.98, 5.35) adjusting for age, race, symptomatic presentation, and skull-based location. Moreover, a WHO grade II/III meningioma was substantially less likely to be observed in asymptomatic patients (OR: 0.15, 95% CI: 0.04, 0.42), and in patients with a skull-based tumour (OR: 0.40, 95% CI: 0.24, 0.66), adjusting for other factors. Male gender, symptomatic tumour, and a non-skull base location were independently associated with WHO grade II/III meningioma.
Conclusion: These findings may shed additional light on the underlying pathogenesis of meningioma.
Materials and Methods: Patients were participants in a multicentre epidemiologic study of risk factors for primary brain tumors including meningioma recruited from September 2005 to November 2019. We included patients 18 or older with a recent diagnosis of a primary intracranial meningioma of any subtype (ICD9/10: 9530-0, 9531-0, 9532-0, 9537-0, 9533-0, 9534-0, 9530-0, 9538-1, 9538-3) who were enrolled at neuro-oncology and neuro-surgery clinics in the southeastern U.S.
Results: The median patient age was 58 years (IQR: 48-68) and the majority of patients were female ( n = 415; 72.7%) and Caucasian ( n = 516; 90.4%). Most patients were symptomatic ( n = 460; 80.6%) and their tumours more commonly occurred in a non-skull base location ( n = 298; 52.2%). A total of 86 patients (15.0%) had a WHO grade II/III meningioma. Compared to patients with WHO grade I tumours, patients with WHO II/III meningiomas were over 3-times more likely to be male (odds ratio (OR): 3.25; 95% confidence interval (CI): 1.98, 5.35) adjusting for age, race, symptomatic presentation, and skull-based location. Moreover, a WHO grade II/III meningioma was substantially less likely to be observed in asymptomatic patients (OR: 0.15, 95% CI: 0.04, 0.42), and in patients with a skull-based tumour (OR: 0.40, 95% CI: 0.24, 0.66), adjusting for other factors. Male gender, symptomatic tumour, and a non-skull base location were independently associated with WHO grade II/III meningioma.
Conclusion: These findings may shed additional light on the underlying pathogenesis of meningioma.